3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
3
Neoplasms
2
Colonic Neoplasms
2
Adenomatous Polyposis Coli
2
Adenoma
2
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polyps
1
Overweight
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Neoplastic Syndromes, Hereditary
1
Neoplasms, Germ Cell and Embryonal
1
Medulloblastoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hepatoblastoma
1
Hepatitis
1
Genetic Diseases, Inborn
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Duodenal Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Chemical and Drug Induced Liver Injury
1
Central Nervous System Neoplasms
1
Interventions
Oxaliplatin
3
Irinotecan
3
Fluorouracil
3
Capecitabine
3
Bevacizumab
3
Leucovorin
2
Colonoscopy
2
Bisacodyl
2
Aspirin
2
lutetium Lu 177 dotatate
1
guadecitabine
1
copper dotatate CU-64
1
camrelizumab
1
apatinib
1
aldesleukin
1
XELOX
1
Ursodeoxycholic Acid
1
Trastuzumab
1
Suction
1
Simvastatin
1
Radiotherapy
1
Polyethylene Glycols
1
Oviposition
1
Lutetium-177
1
Lutetium
1
Ileostomy
1
Folfox protocol
1
Drainage
1
Cyclophosphamide
1
Chemoradiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Intestinal Neoplasms
×
Ursodeoxycholic Acid
×
Clear all
NCT00808743
2013-05-16
PreDuoFAP
Radboud University Medical Center
Phase 2/3
Completed
37 enrolled